"name","description","label","uuid:ID","instanceType","id","text"
"OBJ1","Main objective","","c08eda09-4331-47de-a7df-fd8f49efe5c1","Objective","Objective_1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])."
"OBJ2","Safety","","faaf03f8-da47-439c-8b7d-96dad43f5dde","Objective","Objective_2","To document the safety profile of the xanomeline TTS."
"OBJ3","Behaviour","","d89c3070-a427-4e1d-80cd-b0b8ba6a6b8f","Objective","Objective_3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas."
"OBJ4","","","e02634e2-c3b4-4df3-9f7c-cb1d02302ea3","Objective","Objective_4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5)."
"OBJ5","","","71846b63-eb2f-4a03-bd39-d6a47af4d8a3","Objective","Objective_5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2)."
"OBJ6","","","e42b3c89-1a59-4344-97dd-53edc7bfb0c4","Objective","Objective_6","To assess the treatment response as a function of Apo E genotype."
